Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
Background and Objective: Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI. Patients are randomized to receive periinterventional intravenous BQ-123 or placebo.

Detailed Description
-----------------
Background and Objective: Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. We have previously shown that thrombectomy in ST-elevation myocardial infarction (STEMI) accelerates ST-segment resolution, possibly by preventing distal embolization. Therefore, we analyzed the vasoconstrictor concentration of acute coronary thrombi, and found high concentrations of endothelin (ET) which correlated with the magnitude of ST-segment resolution within one hour of percutaneous coronary intervention (PCI). Furthermore, ET-receptor blockade by tezosentan significantly repressed vasoconstriction in an in-vitro model using porcine coronary artery rings incubated with coronary thrombus homogenates extracted from STEMI patients. The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI. Methods: Fifty eligible patients will be randomized to receive periinterventional intravenous BQ-123 or placebo. The primary endpoint of the study will be microvascular function evaluated by cardiac magnetic resonance tomography.

Official Title
-----------------
Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction

Conditions
-----------------
ST-Elevation Myocardial Infarction

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: BQ-123


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: STEMI patients (defined as: Evidence of ischemic chest pain for >30 minutes within <12 hours and new ST-segment elevation for ≥2 mm in two or more contiguous electrocardiographic leads or in case of a true posterior infarction reciprocal ST-segment depressions in in V1 and V2 >1mm and/or elevated serum creatine phosphokinase or twofold elevation of troponin-T), aged 18 years and above, who undergo primary percutaneous revascularization (PCI) and have confirmed initial TIMI 0 or 1 in the infarct related coronary artery. Exclusion Criteria: Significant liver disease Thrombolytic therapy History of prior myocardial infarction Current atrial fibrillation History of congestive heart failure History of migraine headache Significant valvular heart disease, primary myocardial disease Cardiogenic shock (sRR <90mmHg or need for inotropic support) Child-bearing potential Inability to read, understand and sign the informed consent Life expectancy <3y Prior organ transplantation Medication with konazoles, ritonavir, rifampicin and sulfonyl-urea derivatives Participation in another clinical study Metal implants contraindicating CMR

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>Placebo | Drug: Placebo<br>* Peri-interventional<br>* Other names: sodium salt;|
| Active Comparator: 2<br>BQ-123 | Drug: BQ-123<br>* Peri-interventional<br>* Other names: Cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu) sodium salt;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Myocardial perfusion determined by CMR |  | 3 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Final infarct size determined by CMR |  | 3 days | 
| Left ventricular function determined by CMR |  | 3 days/ 6 months (6-months Remodeling-substudy) | 
| Plasma NT-BNP |  | 30 days/ 6 months (6-months substudy) | 
| Enzymatic infarct size (CK levels) |  | 3 days | 
| ECG ST-segment resolution |  | 1 hour | 
| Markers of inflammation |  | 24 hours/ 30 days | 
| Major adverse cardiac events (MACE) (cardiovascular death, re-hospitalization for unstable angina and AMI, hospitalization for worsening heart failure) |  | 30 days | 
| Liver function |  | 24hours/ 3 days/ 30 days | 
| Event free survival |  | 6 months (6-months substudy) | 
| Holter ECG |  | 3 days / 30 days (EP-substudy) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infarction, Endothelin, Perfusion